169503-35-9

Upstream product

• 280775-74-8 4-(1H-imidazol-4-ylmethyl)benzonitrile 
• 76-83-5 trityl chloride 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 
• 106-93-4 ethylene dibromide 
• 17201-43-3 4-cyanobenzyl bromide 
• 198205-94-6 acetic acid (4-cyano-phenyl)-(1-trityl-1H-imidazol-4-yl)methyl ester 
• 557-91-5 1,1-Dibromoethane 
• 37594-78-8 1-(4-iodo-trityl)-1H-imidazole 
• 105-07-7 4-cyanobenzaldehyde 
• 169503-34-8 4-[hydroxy-(1-trityl-1H-imidazol-4-yl)methyl]benzonitrile 

Downstream Products

• 224585-45-9 N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea 
• 169503-50-8 [4-(1-trityl-1H-imidazol-4-ylmethyl)-phenyl]-methanol 
• 169503-49-5 4-(1-trityl-1H-imidazol-4-ylmethyl)-benzoic acid ethyl ester 

Relevant academic research and scientific papers

4-Benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists

Research on the therapeutic applications of the histamine H3 receptor (H3R) has traditionally focused on antagonists/inverse agonists. In contrast, H3R agonists have received less attention despite their potential use in s

Prenyl transferase inhibitors

A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R23); and the remaining substituents are as defined in the disclosure.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors

PCT No. PCT/US97/06257 Sec. 371 Date Oct. 2, 1998 Sec. 102(e) Date Oct. 2, 1998 PCT Filed Apr. 1, 1997 PCT Pub. No. WO97/36876 PCT Pub. Date Oct. 9, 1997The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Inhibitors of prenyl-protein transferase

The present invention is directed to compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras